Company intelligence / Profile preview

Transcutan

Stockholm, Sweden

Ownership: Private
Development stage: Other

Overview

Transcutan is a Swedish biotechnology company focused on developing innovative topical treatments for skin cancer and precancerous lesions. The company's lead program, T01, is a proprietary topical formulation of a well-known active substance designed to treat actinic keratosis and non-melanoma skin cancer. By optimizing transdermal delivery, Transcutan aims to provide more effective and less invasive alternatives to current surgical or destructive therapies. The company is currently advancing its clinical pipeline to address significant unmet needs in the dermatology market.

Therapeutic areas: OncologyDermatology
Modalities: Small moleculeTopical formulation
Industry: Biotech

Beyond the preview

Go deeper on Transcutan.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Transcutan.

Explore the full profile